Treatment Options Reviewed for Herpes Simplex Viral Keratitis

This article originally appeared here.
Share this content:
Treatment Options Reviewed for Herpes Simplex Viral Keratitis
Treatment Options Reviewed for Herpes Simplex Viral Keratitis

TUESDAY, June 14, 2016 (HealthDay News) -- There is a need for development of new anti-herpetic compounds with different mechanisms of action for herpes simplex viral keratitis (HSVK), according to a review published online June 6 in Clinical & Experimental Ophthalmology.

Noting that HSVK is an important cause of visual impairment, Michael Tsatsos, M.D., Ph.D., from the Dorset County Hospital NHS Foundation Trust in Dorchester, U.K., and colleagues reviewed the evidence on the pathogenesis of different HSVK disease modalities.

The researchers note that current therapeutic practice is based on outcomes from the Herpetic Eye Disease Studies I and II, which examined the effectiveness of oral acyclovir in management of stromal herpes keratitis. Newer medications such as valacyclovir may have a superior therapeutic effect to acyclovir; the reduced dosage may aid compliance, and increased bioavailability could increase efficacy. With the increased incidence of acyclovir-resistant infections, there is a need to develop new anti-herpetic compounds with different mechanisms of action, which will be safe and effective against viral strains that are drug resistant; antiviral agents such as foscarnet and cidofovir may be used. Topical ganciclovir is a front-line topical antiviral drug which exhibits less toxicity and offers a simpler dosing regimen.

"Furthering the understanding of herpetic eye disease and promoting the development of more targeted therapy will undoubtedly alter our practice in the future and reduce the significant disease burden associated with this condition," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »